Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

A5844

Sigma-Aldrich

Monoclonal Anti-c-Abl antibody produced in mouse

clone ABL-148, ascites fluid

Sign Into View Organizational & Contract Pricing

Synonym(s):
Anti-ABL, Anti-BCR-ABL, Anti-CHDSKM, Anti-JTK7, Anti-bcr/abl, Anti-c-ABL, Anti-c-ABL1, Anti-p150, Anti-v-abl
MDL number:
UNSPSC Code:
12352203
NACRES:
NA.44

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

ascites fluid

antibody product type

primary antibodies

clone

ABL-148, monoclonal

mol wt

antigen 145 kDa

species reactivity

monkey, rat, human, mouse, bovine

technique(s)

flow cytometry: suitable
immunocytochemistry: suitable
immunoprecipitation (IP): suitable
microarray: suitable
western blot: 1:2,000 using human melanoma cell extract

isotype

IgG2a

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... ABL1(25)
mouse ... Abl1(11350)
rat ... Abl1(311860)

General description

The c-Abl protein contains three high mobility group-like domains that bind to AT-rich DNA in a cooperative manner.
c-Abl is a proto-oncogene product that belongs to Tyr protein kinase family. It has a crucial role in different cellular processes like- differentiation, adhesion and regulates DNA damage-induced apoptosis.

Specificity

Mouse anti-c-Abl antibody reacts specifically with an epitope present in the SH2 domain of the c-Abl. The product has also shown reactivity for c-Abl of monkey, rat, bovine, mouse and human.

Immunogen

recombinant c-Abl, SH2 domain.

Application

Monoclonal anti-c-Abl antibody can be used in western blotting (diluted 1:2000) using melanoma cell extract from human. It can also be used in microarray and flow cytometry. Monoclonal anti-c-Abl antibody can be used for studying the mechanism of signaling pathways involving c-Abl. It may also be used for immunoprecipitation and immunocytochemistry.

Biochem/physiol Actions

Cytoplasmic c-Abl regulates SH2/SH3 adaptor protein cytoskeleton-associated adaptor protein (Crk) and the Crk-binding protein p130cas. Nuclear c-Abl has been implicated in the regulation of cell cycle-dependent and DNA damage-induced gene expression.

Target description

c-Abl is a non-receptor tyrosine kinase with both cytoplasmic and nuclear functions. The Abl oncogen has been implicated in several human leukemias including nearly all chronic myelocytic leukemias.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

常规特殊物品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

c-Abl: activation and nuclear targets
Shaul Y
Cell Death and Differentiation, 7(1), 10-10 (2000)
Cytoplasmic c-Abl provides a molecular `Rheostat?controlling carcinoma cell survival and invasion
Kain KH, et al.
Oncogene, 22(38), 6071-6071 (2003)
Lukasz Skora et al.
European journal of haematology, 96(5), 502-506 (2015-07-15)
Binding of tyrosine kinase inhibitors such as imatinib was shown to induce a novel open-inhibited conformation of BCR-ABL, in which Tyr245 is exposed and prone to phosphorylation. To evaluate whether this leads to priming of the kinase in cellular systems
Lukasz Skora et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(47), E4437-E4445 (2013-11-06)
Successful treatment of chronic myelogenous leukemia is based on inhibitors binding to the ATP site of the deregulated breakpoint cluster region (Bcr)-Abelson tyrosine kinase (Abl) fusion protein. Recently, a new type of allosteric inhibitors targeting the Abl myristoyl pocket was
Michela Restelli et al.
Human molecular genetics, 24(15), 4185-4197 (2015-04-26)
The p63 transcription factor, homolog to the p53 tumor suppressor gene, plays a crucial role in epidermal and limb development, as its mutations are associated to human congenital syndromes characterized by skin, craniofacial and limb defects. While limb and skin-specific

Articles

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service